BACTI_B: Strong revenue growth and profitability turnaround driven by licensing, despite orthopedic setback

About this update from Bactiguard Holding Ab

License-driven growth led to a 17.3% revenue increase and positive EBITDA in 2024, with improved margins and cash flow. The Zimmer Biomet agreement termination prompted a review of financial targets, while new licensing and R&D initiatives support future growth. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Bactiguard Holding Ab